Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 29 July 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Certolizumab pegol improves mucosal lesions in ileocolonic Crohn's disease

The latest issue of Gut reports endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol.

News image


Dr Xavier Hébuterne from France evaluated the efficacy of certolizumab pegol (CZP) in improving endoscopic lesions in patients with active ileocolonic Crohn's disease.

The team performed a phase IIIB multicenter open-label clinical trial, and enrolled 89 adult patients with active endoscopic disease.
 
Patients received subcutaneous certolizumab pegol 400 mg at weeks 0, 2 and 4, and every 4 weeks up to week 52. 

The researchers found that endoscopic evaluations were performed at weeks 0, 10 and 54. 

The team's primary outcome was mean change in CDEIS score at week 10.
 
Secondary outcome measures included endoscopic response, complete remission and mucosal healing at weeks 10 and 54.
Endoscopic response at week 10 was 54%
Gut
The team of doctors observed that the mean CDEIS score was 15 at baseline.
 
The researchers noted that the mean decrease in CDEIS score at week 10 was 6. 

Rates of endoscopic response, endoscopic remission, complete endoscopic remission and mucosal healing at week 10 were 54%, 37%, 10% and 4%, respectively. 

The researchers found that that at week 54 the corresponding rates were 49%, 27%, 14% and 8%, respectively. 
 
The safety profile was consistent with that of previous certolizumab pego trials.
 
Dr Xavier and team concludes, "Following certolizumab pego treatment in patients with active Crohn's disease, endoscopic lesions were improved as shown by the decrease in mean CDEIS score and by endoscopic response and remission rates."
 
"These benefits were achieved as early as week 10 and were generally maintained through week 54."

Gut 2013;62:201-208 
11 January 2013

Go to top of page Email this page Email this page to a colleague

 29 July 2016 
Susceptibility loci for gallstone disease
 29 July 2016 
H. pylori clarithromycin resistance in the USA
 29 July 2016 
Tool to diagnose Helicobacter-negative gastritis
 28 July 2016 
HCV eradication in cirrhotic patients
 28 July 2016 
Hep B screening and immunosuppressive therapy
 28 July 2016 
Pancreatitis after ERCP
 27 July 2016 
Gluten exposure in patients with celiac disease
 27 July 2016 
Bleeding GI recurrence with aspirin use
 27 July 2016 
IBD during pregnancy
 26 July 2016 
Gut microbiota and IBD
 26 July 2016 
Neighborhood variation in the use of laparoscopy for colon cancer
 26 July 2016 
Post-infectious IBS after C. diff
 25 July 2016 
Antibiotic prophylaxis for open colectomies
 25 July 2016 
Steroids in eosinophilic esophagitis
 25 July 2016 
Prevention of post-ERCP pancreatitis
 22 July 2016 
Upper GI lesions at primary diagnosis in IBD
 22 July 2016 
Duodenal villous atrophy and celiac disease
 22 July 2016 
Fecal calprotectin and IBD
 21 July 2016 
Radiofrequency ablation in Barrett's
 21 July 2016 
HCV eradication and inflammation in cirrhotic patients
 21 July 2016 
Surveillance of Barrett's
 20 July 2016 
Nonselective β-blockers and survival in cirrhosis
 20 July 2016 
Adolescent body mass index and and colorectal cancer risk
 20 July 2016 
Genetic biomarkers and IBD treatment response
 19 July 2016 
Prevention of chemotherapy-induced nausea and vomiting
 19 July 2016 
Screening diabetic patients for NAFLD
 19 July 2016 
Longterm clinical follow-up of living liver donors
 18 July 2016 
Rectal neuroendocrine tumors
 18 July 2016 
Liver cancer prediction scores in Hep B
 18 July 2016 
Liver stiffness measurement in chronic liver disease
 15 July 2016 
Patient reported outcomes in celiac disease
 15 July 2016 
Tonsillectomy and IBD risk
 15 July 2016 
Trainee IBD education in the USA
 14 July 2016 
Screening for familial pancreatic cancer
 14 July 2016 
Fecal calprotection for IBD prognosis
 14 July 2016 
Perianal surgery risk in Crohn's
 13 July 2016 
Psychological comorbidity and postinfectious IBS
 13 July 2016 
Lung transplant outcomes in Hep C
 13 July 2016 
Graft selection strategy in living donor liver transplants
 12 July 2016 
Surveillance endoscopy in Barrett's esophagus
 12 July 2016 
Therapy for iron deficiency anemia in IBD
 12 July 2016 
Treatment of pediatric acute liver failure
 11 July 2016 
Transition to adulthood in celiac disease
 11 July 2016 
Disturbed sleep and IBS
 11 July 2016 
Factors that influence access to liver transplant
 08 July 2016 
Mortality and peptic ulcers
 08 July 2016 
Genetic risk score and body mass index
 08 July 2016 
Statins and cirrhosis in Hep B
 07 July 2016 
Predicting food triggers in eosinophilic esophagitis
 07 July 2016 
Extraperitoneal vs transperitoneal colostomy for hernia
 07 July 2016 
Predictors fecal transplant failure in C. diff infection
 06 July 2016 
Therapies for Hep B cure
 06 July 2016 
Hospital volume and liver cancer survival
 06 July 2016 
Adverse events after outpatient colonoscopy
 05 July 2016 
Colorectal surgery and dialysis
 05 July 2016 
Exercise and gastroesophageal reflux
 05 July 2016 
Non-invasive scoring systems for fibrosis in NAFLD
 04 July 2016 
Autoimmunity in eosinophilic esophagitis and families
 04 July 2016 
Rectal cancer surgery checklist
 04 July 2016 
Guidelines on PPI and NSAID prescription

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us